Establishment and clinical application of SARS-CoV-2 catch column

Springer Science and Business Media LLC - Tập 27 - Trang 279-287 - 2022
Yoshitaka Isaka1, Taku Yoshiya2,3, Chikako Ono4,5, Akinori Uchiyama6, Haruhiko Hirata7, Shigeto Hamaguchi8, Satoshi Kutsuna8, Yoshitsugu Takabatake1, Ryotaro Saita9, Tomomi Yamada9, Atsushi Takahashi1, Masaya Yamato10, Yukie Nohara2, Shugo Tsuda2, Itsuki Anzai11, Tomonori Kimura12, Yoshito Takeda7, Kazunori Tomono13, Yoshiharu Matsuura4,5
1Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan
2Peptide Institute Inc, Ibaraki, Japan
3Institute for Protein Research, Osaka University, Suita, Japan
4Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Suita, Japan
5Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
6Department of Intensive Care Unit, Osaka University Hospital, Suita, Japan
7Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan
8Department of Infection Control, Osaka University Hospital, Suita, Japan
9Department of Medical Innovation, Osaka University Hospital, Suita, Japan
10Division of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan
11Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
12KAGAMI Project, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan
13Osaka Institute of Public Health, Osaka, Japan

Tóm tắt

A certain number of patients with coronavirus disease 2019 (COVID-19), particularly those who test positive for SARS-CoV-2 in the serum, are hospitalized. Further, some even die. We examined the effect of blood adsorption therapy using columns that can eliminate SARS-CoV-2 on the improvement of the prognosis of severe COVID-19 patients. This study enrolled seven patients receiving mechanical ventilation. The patients received viral adsorption therapy using SARS-catch column for 3 days. The SARS-catch column was developed by immobilizing a specific peptide, designed based on the sequence of human angiotensin-converting enzyme 2 (hACE2), to an endotoxin adsorption column (PMX). In total, eight types of SARS-CoV-2-catch (SCC) candidate peptides were developed. Then, a clinical study on the effects of blood adsorption therapy using the SARS-catch column in patients with severe COVID-19 was performed, and the data in the present study were compared with historical data of severe COVID-19 patients. Among all SCC candidate peptides, SCC-4N had the best adsorption activity against SARS-CoV-2. The SARS-catch column using SCC-4N removed 65% more SARS-CoV-2 than PMX. Compared with historical data, the weaning time from mechanical ventilation was faster in the present study. In addition, the rate of negative blood viral load in the present study was higher than that in the historical data. The timely treatment with virus adsorption therapy may eliminate serum SARS-CoV-2 and improve the prognosis of patients with severe COVID-19. However, large-scale studies must be performed in the future to further assess the finding of this study (jRCTs052200134).

Tài liệu tham khảo

Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11(1):5493. Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J, et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. Clin Infect Dis. 2021;73(9):e2995–3001. Jacobs JL, Bain W, Naqvi A, Staines B, Castanha PMS, Yang H, et al. SARS-CoV-2 viremia is associated with COVID-19 severity and predicts clinical outcomes. Clin Infect Dis. 2022;74(9):1525–33. Li Y, Schneider AM, Mehta A, Sade-Feldman M, Kays KR, Gentili M, et al. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J Clin Invest. 2021;131(13):e148635. Rodríguez-Serrano DA, Roy-Vallejo E, Zurita Cruz ND, Martín Ramírez A, Rodríguez-García SC, Arevalillo-Fernández N, et al. Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients. Sci Rep. 2021;11(1):13134. Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease 2019. J Med Virol. 2021;93(5):3165–75. Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, et al. Actionable druggable genome-wide mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med. 2021;27(4):668–76. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–4. Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8(11):1154–8. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV Antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23): e81. Katagiri D, Ishikane M, Asai Y, Izumi S, Takasaki J, Katsuoka H, et al. Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J Clin Apheresis. 2021;36(3):313–21. Schmidt JJ, Borchina DN, Van’t Klooster M, Bulhan-Soki K, Okioma R, Herbst L, et al. Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry. Nephrol Dial Transplant. 2022;37(4):673–80. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–4. Hashizume M, Gonzalez G, Ono C, Takashima A, Iwasaki M. Population-specific ACE2 single-nucleotide polymorphisms have limited impact on SARS-CoV-2 infectivity in vitro. Viruses. 2021;13(1):67. Yoshida S, Ono C, Hayashi H, Fukumoto S, Shiraishi S, Tomono K, et al. SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. Sci Rep. 2021;11(1):5934. Goodman M, Chorev M. On the concept of linear modified retro-peptide structures. Acc Chem Res. 1979;12(1):1–7. Li C, Pazgier M, Li J, Liu M, Zou G, Li Z, et al. Limitations of peptide retro-inverso isomerization in molecular mimicry. J Biol Chem. 2010;285(25):19572–81.
Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 27

279-287

Thông tin tác giả